Loading…
Blaine Labs Inc, a pharmaceutical manufacturer, received an FDA Warning Letter on May 5, 2020, regarding drug products under its purview. While the specific violations cannot be determined from the available metadata, the warning indicates regulatory compliance concerns serious enough to warrant formal FDA enforcement action. The letter was issued by the FDA's drug regulatory authority, though the specific issuing office is not documented in this summary. Additional details regarding the nature and scope of violations would require review of the full Warning Letter text.